BTIG Reiterates Buy on Akebia Therapeutics, Maintains $4 Price Target
BTIG analyst Julian Harrison reiterates Akebia Therapeutics (NASDAQ:AKBA) with a Buy and maintains $4 price target.
Stocks · News reference
Why SiTime Shares Are Trading Higher By Over 30%; Here Are 20 Stocks Moving Premarket
SiTime Corp (SITM) stock rose 30.7% in pre-market trading after beating earnings and sales estimates. Other gainers include CLRO, WYHG, SURG, PAVS, MGRX, CELZ, SOUN, WPP, HNST. YXT was the only loser after CFO resignation.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Akebia Therapeutics Doses First Patient In Phase 2 Basket Trial Of Ebribafusp In Rare Complement-Mediated Kidney Diseases
Open-label Phase 2 trial evaluating ebribafusp for the treatment of IgA nephropathy, lupus nephritis and C3 glomerulopathyInitial data is expected in 2027
WestPark Capital Initiates Coverage On Akebia Therapeutics with Buy Rating, Announces Price Target of $4.5
Leerink Partners Downgrades Akebia Therapeutics to Market Perform, Announces $1 Price Target
Leerink Partners analyst Roanna Ruiz downgrades Akebia Therapeutics (NASDAQ:AKBA) from Outperform to Market Perform and announces $1 price target.
8-K filing — CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ)
Filed: 2026-08-31 AccNo: 0001477932-26-005329 Size: 947 KB Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 5.07: Submission of Matters to a Vote of Security Holders Item 9.01: Financial Statements and Exhibits
Creative Medical shares are trading higher after the company announced that all patients have now been enrolled and treated across its FDA-cleared ADAPT clinical trial of CELZ-201 / Olastrocel, including the opioid expansion cohort.